Integra LifeSciences Holdings Corporation
IARTNASDAQHealthcare● Active
$16.94
$-0.05(-0.29%)
Market Cap$1.3B
P/E Ratio—
52W High$17.83
52W Low$8.7
Integra LifeSciences Holdings Corporation (IART) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IART · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.52B) | ($0.01B) | $0.07B | $0.18B | $0.17B |
| Depreciation & Amort. | $0.00B | $0.14B | $0.12B | $0.12B | $0.12B |
| Stock-Based Comp. | $0.00B | $0.02B | $0.02B | $0.03B | $0.04B |
| Change in Working Capital | ($0.03B) | ($0.03B) | ($0.08B) | ($0.04B) | $0.02B |
| Net Cash from Operations | $0.05B | $0.13B | $0.14B | $0.26B | $0.31B |
| Investing Activities | |||||
| Capital Expenditure | ($0.08B) | ($0.10B) | ($0.07B) | ($0.05B) | ($0.05B) |
| Purchases of Investments | $0.00B | ($0.05B) | ($0.03B) | ($0.00B) | $0.00B |
| Sales of Investments | $0.00B | $0.05B | $0.01B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.11B) | ($0.39B) | ($0.09B) | ($0.06B) | ($0.16B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.00B) | ($0.05B) | ($0.28B) | ($0.13B) | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.05B | $0.30B | $0.05B | ($0.11B) | ($0.10B) |
| Net Cash from Financing | $0.03B | $0.24B | ($0.23B) | ($0.25B) | ($0.10B) |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.03B) | $0.02B | $0.07B | $0.22B | $0.26B |
| FCF Margin %(computed) | -1.90% | 1.55% | 4.74% | 13.96% | 17.14% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Integra LifeSciences Holdings Corporation data
About Integra LifeSciences Holdings Corporation (IART) Cash Flow Statement
Integra LifeSciences Holdings Corporation generated operating cash flow of $0.05B and free cash flow of ($0.03B) for 2025 — a FCF margin of -1.90%. Capital expenditure was ($0.08B).
Frequently asked questions
IART · 4 questionsIntegra LifeSciences Holdings Corporation generated free cash flow of ($0.03B) for 2025, down 224.4% year-over-year.
IART free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10